Emerald Health Therapeutics Introduces Unique Premium CBD Oil SYNC 25 to British Columbia Recreational Marketplace
May 17 2019 - 7:58AM
Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX:
EMHTF) has shipped 6,000 40 ml units of its SYNC 25 CBD oil to the
British Columbia Liquor Distribution Branch (BCLDB). The
Emerald-branded pure CBD oil offers consumers a non-THC, smoke-free
product alternative.
“We are pleased to offer our new Emerald-branded
wellness product SYNC 25 to the recreational marketplace in British
Columbia,” said Dr. Avtar Dhillon, President and Executive Chairman
of Emerald. “The introduction of SYNC 25 marks the next step in our
product growth strategy to develop innovative and quality consumer
products that respond to a growing demand while providing higher
profit margins.”
The SYNC 25 CBD oil product was extracted by
MediPharm Labs Inc., a wholly-owned subsidiary of MediPharm Labs
Corp. (TSXV: LABS; OTCQX: MEDIF) (“MediPharm Labs”).
“Emerald’s success in bringing products to the
market that address the significant consumer demand for CBD
demonstrates how MediPharm Labs’ specialized expertise in
extraction empowers our partner brands with an advanced oil
strategy and a competitive advantage,” said Pat McCutcheon, Chief
Executive Officer of MediPharm Labs. “We look forward to providing
high-quality, pharmaceutical-like cannabis concentrates as Emerald
expands on its product growth strategy in the future.”
Emerald’s SYNC 25 CBD oil is currently available for purchase
at:
https://www.bccannabisstores.com/products/sync-25-cannabis-oil.
About MediPharm Labs Corp.
Founded in 2015, MediPharm Labs has the
distinction of being the first company in Canada to become a
licensed producer for cannabis oil production under the ACMPR
without first receiving a cannabis cultivation licence. This expert
focus on cannabis concentrates from our cGMP (current Good
Manufacturing Practices) and ISO standard clean rooms and critical
environments laboratory, allows MediPharm Labs to produce purified,
pharmaceutical-like cannabis oil and concentrates for advanced
derivative products. MediPharm Labs has invested in an expert,
research-driven team, state-of-the-art technology, downstream
extraction methodologies and purpose-built facilities to deliver
pure, safe and precisely-dosed cannabis products to patients and
consumers. MediPharm Labs’ private label program is a high margin
business for the Company, whereby it opportunistically procures dry
cannabis flower and trim from its numerous product supply partners,
to produce proprietary cannabis oil concentrate products for resale
globally on a private label basis.
Through its subsidiary, MediPharm Labs Australia Pty. Ltd.,
MediPharm Labs has also completed its application process with the
federal Office of Drug Control to extract and import medical
cannabis products in Australia.
For further information about MediPharm Labs Corp :
Please visit www.medipharmlabs.com
About Emerald Health Therapeutics,
Inc.
Emerald Health Therapeutics, Inc. is a Canadian
licensed producer of cannabis. Its 50%-owned Pure Sunfarms joint
venture in BC is licensed and in full production in 1.03 million
square feet of the first of two 1.1 million square foot
greenhouses. The capacity of each greenhouse is estimated to exceed
75,000 kg of cannabis annually. Emerald’s Verdélite operation in
Québec is completing the build-out of its 88,000 square foot indoor
cultivation facility and is scaling up production. Emerald secured
over 500 acres of hemp harvest in 2018 and has contracted for
approximately 1000 acres in 2019 to 2022, with the objective of
extracting low-cost cannabidiol. Emerald has secured exclusive
strategic partnerships for large scale extraction and softgel
encapsulation, as well as for proprietary technology to enhance
cannabinoid bioavailability. Its team is highly experienced in life
sciences, product development, large-scale agri-business, and
marketing, and is focused on developing proprietary, value-added
cannabis products for medical and adult-use customers.
Emerald is part of the Emerald Health group,
which represents a broad array of companies focused on developing
pharmaceutical, botanical, and nutraceutical products aimed at
providing wellness and medical benefits by interacting with the
human body’s endocannabinoid system.
For further information about Emerald Health Therapeutics.
Please visit www.emeraldhealth.ca or contact: Rob Hill, Chief
Financial Officer (800) 757 3536 Ext. # 5
Emerald Investor Relations (800) 757 3536 Ext.
#5invest@emeraldhealth.ca
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking
Statements: Certain statements made in this press release that are
not historical facts are forward-looking statements and are subject
to important risks, uncertainties and assumptions, both general and
specific, which give rise to the possibility that actual results or
events could differ materially from our expectations expressed in
or implied by such forward-looking statements. Such statements
include projected job creation figures at our operating facilities;
production and processing capacity of various facilities; expansion
of facilities; and anticipated production costs.
We cannot guarantee that any forward-looking
statement will materialize, and readers are cautioned not to place
undue reliance on these forward-looking statements. These
forward-looking statements involve risks and uncertainties related
to, among other things, failure to obtain regulatory approvals;
failure to obtain necessary financing; results of production and
sale activities; results of scientific research; regulatory
changes; changes in prices and costs of inputs; demand for labour;
demand for products; as well as the risk factors described in the
Company’s annual information form and other regulatory filings. The
forward-looking statements contained in this press release
represent our expectations as of the date hereof. Forward-looking
statements are presented for the purpose of providing information
about management's current expectations and plans and allowing
investors and others to obtain a better understanding of our
anticipated operating environment. Readers are cautioned that such
information may not be appropriate for other purposes. The Company
undertakes no obligations to update or revise such statements to
reflect new circumstances or unanticipated events as they occur,
unless required by applicable law.
A photo accompanying this announcement is available at
http://www.globenewswire.com/NewsRoom/AttachmentNg/3efcc108-9167-4b3b-91db-f094e2d7ad3f
Emerald Health Therapeut... (TSXV:EMH)
Historical Stock Chart
From Jul 2024 to Aug 2024
Emerald Health Therapeut... (TSXV:EMH)
Historical Stock Chart
From Aug 2023 to Aug 2024